title: Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women.
abstract: BACKGROUND
  There is no consensus on the standard treatment options for female pattern androgenetic alopecia (AGA). Efficacy of finasteride in women is controversial. The purpose of this study was to evaluate the clinical efficacy and safety of 5 mg/day oral finasteride in normoandrogenic postmenopausal woman.
  
  
  METHODS
  A total of 40 normoandrogenic postmenopausal women with AGA was enrolled in this study. They were treated with oral finasteride 5 mg/day for 18 months. Efficacy was evaluated by patient's satisfaction and global photograph assessment. All the 40 patients completed 18 months of finasteride treatment schedule.
  
  
  RESULTS
  After 6 months, 22 patients referred significant improvement, 12 moderate improvement, and 6 no improvement. Regarding to global photo assessment, 8 patients showed no improvement, 16 showed moderate improvement and 16 showed significant improvements at the 6(th) month. A slight improvement was observed over time from 6 to 12 and 18 months observation. Maintained libido reduction was referred by four patients and liver enzymes increase was observed in one patient. Older patients were more prone to worse response.
  
  
  CONCLUSIONS
  Finasteride 5 mg/day is effective and safe for the treatment of female AGA in postmenopausal women in the absence of clinical or laboratory signs of hyper-androgenism.
authors: Dermatology Center, Hospital CUF Descobertas, Lisbon, Portugal.
authors: R
authors: R
authors: Oliveira-Soares
authors: J Maia
authors: JM
authors: E Silva
authors: M Peres
authors: MP
authors: Correia
authors: Marisa C
authors: MC
authors: André
keywords: Female androgenetic alopecia; finasteride; normo-androgenetic; postmenopausal
references: J Eur Acad Dermatol Venereol. 2011 Feb;25(2):211-4
references: 20569283
references: J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):768-76
references: 11050579
references: J Am Acad Dermatol. 2002 Nov;47(5):733-9
references: 12399766
references: Br J Dermatol. 2002 Oct;147(4):812-3
references: 12366441
references: J Investig Dermatol Symp Proc. 2003 Jun;8(1):20-3
references: 12894990
references: Arch Dermatol. 2006 Mar;142(3):298-302
references: 16549704
references: Dermatology. 2004;209(3):202-7
references: 15459533
references: J Am Acad Dermatol. 2010 Aug;63(2):252-8
references: 20605255
references: J Drugs Dermatol. 2005 Sep-Oct;4(5):637-40
references: 16167423
references: J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89
references: 9777765
references: Acta Derm Venereol. 2004;84(6):488-9
references: 15844649
references: Dermatol Ther. 2011 Mar-Apr;24(2):296-300
references: 21410621
references: J Cosmet Dermatol. 2007 Mar;6(1):9-13
references: 17348989
references: Br J Dermatol. 1977 Sep;97(3):247-54
references: 921894